|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Costs Associated With the Primary Prevention of Type 2 Diabetes Mellitus in the Diabetes Prevention Program
From the Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, Rockville, Maryland
OBJECTIVE—To describe the costs of the Diabetes Prevention Program (DPP) interventions to prevent or delay type 2 diabetes.
RESEARCH DESIGN AND METHODS—We describe the direct medical costs, direct nonmedical costs, and indirect costs of the placebo, metformin, and intensive lifestyle interventions over the 3-year study period of the DPP. Resource use and cost are summarized from the perspective of a large health system and society. Research costs are excluded.
RESULTS—The direct medical cost of laboratory tests to identify one subject with impaired glucose tolerance (IGT) was $139. Over 3 years, the direct medical costs of the interventions were $79 per participant in the placebo group, $2,542 in the metformin group, and $2,780 in the lifestyle group. The direct medical costs of care outside the DPP were $272 less per participant in the metformin group and $432 less in the lifestyle group compared with the placebo group. Direct nonmedical costs were $9 less per participant in the metformin group and $1,445 greater in the lifestyle group compared with the placebo group. Indirect costs were $230 greater per participant in the metformin group and $174 less in the lifestyle group compared with the placebo group. From the perspective of a health system, the cost of the metformin intervention relative to the placebo intervention was $2,191 per participant and the cost of the lifestyle intervention was $2,269 per participant over 3 years. From the perspective of society, the cost of the metformin intervention relative to the placebo intervention was $2,412 per participant and the cost of the lifestyle intervention was $3,540 per participant over 3 years.
CONCLUSIONS—The metformin and lifestyle interventions are associated with modest incremental costs compared with the placebo intervention. The evaluation of costs relative to health benefits will determine the value of these interventions to health systems and society.
Abbreviations: AWP, average wholesale price • CMS, Center for Medicare and Medicaid Services • DPP, Diabetes Prevention Program • IGT, impaired glucose tolerance • LCM, lifestyle case manager • MCM, medication case manager • OGTT, oral glucose tolerance tests
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Kawahara, K. Takahashi, T. Inazu, T. Arao, C. Kawahara, T. Tabata, H. Moriyama, Y. Okada, E. Morita, and Y. Tanaka Reduced Progression to Type 2 Diabetes From Impaired Glucose Tolerance After a 2-Day In-Hospital Diabetes Educational Program: The Joetsu Diabetes Prevention Trial Diabetes Care, October 1, 2008; 31(10): 1949 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. O'Neil and T. A. Nicklas State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health American Journal of Lifestyle Medicine, December 1, 2007; 1(6): 457 - 481. [Abstract] [PDF]
|
|
|
|
|
|
T. J. Hoerger, K. A. Hicks, S. W. Sorensen, W. H. Herman, R. E. Ratner, R. T. Ackermann, P. Zhang, and M. M. Engelgau Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults Diabetes Care, November 1, 2007; 30(11): 2874 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Marrero and R. T. Ackermann Providing Long-Term Support for Lifestyle Changes: A Key to Success in Diabetes Prevention Diabetes Spectr, October 1, 2007; 20(4): 205 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ramachandran, C. Snehalatha, A. Yamuna, S. Mary, and Z. Ping Cost-Effectiveness of the Interventions in the Primary Prevention of Diabetes Among Asian Indians: Within-trial results of the Indian Diabetes Prevention Programme (IDPP) Diabetes Care, October 1, 2007; 30(10): 2548 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Herman Diabetes Epidemiology: Guiding Clinical and Public Health Practice: The Kelly West Award Lecture, 2006 Diabetes Care, July 1, 2007; 30(7): 1912 - 1919. [Full Text] [PDF]
|
|
|
|
|
|
A. Ferrara Increasing Prevalence of Gestational Diabetes Mellitus: A public health perspective Diabetes Care, July 1, 2007; 30(Supplement_2): S141 - S146. [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Ackermann and D. G. Marrero Adapting the Diabetes Prevention Program Lifestyle Intervention for Delivery in the Community: The YMCA Model The Diabetes Educator, January 1, 2007; 33(1): 69 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A.M. Jacobs-van der Bruggen, G. Bos, W. J. Bemelmans, R. T. Hoogenveen, S. M. Vijgen, and C. A. Baan Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk: Results from a modeling study Diabetes Care, January 1, 2007; 30(1): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Ritzwoller, D. Toobert, A. Sukhanova, and R. E. Glasgow Economic analysis of the mediterranean lifestyle program for postmenopausal women with diabetes. The Diabetes Educator, September 1, 2006; 32(5): 761 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Ackermann, D. G. Marrero, K. A. Hicks, T. J. Hoerger, S. Sorensen, P. Zhang, M. M. Engelgau, R. E. Ratner, and W. H. Herman An Evaluation of Cost Sharing to Finance a Diet and Physical Activity Intervention to Prevent Diabetes. Diabetes Care, June 1, 2006; 29(6): 1237 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Johnson, R. Manjunath, C. A. Mansfield, L. J. Clayton, T. J. Hoerger, and P. Zhang High-Risk Individuals' Willingness to Pay for Diabetes Risk-Reduction Programs. Diabetes Care, June 1, 2006; 29(6): 1351 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hardeman, S. Sutton, S. Griffin, M. Johnston, A. White, N. J. Wareham, and A. L. Kinmonth A causal modelling approach to the development of theory-based behaviour change programmes for trial evaluation Health Educ. Res., December 1, 2005; 20(6): 676 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Eddy, L. Schlessinger, and R. Kahn Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes Ann Intern Med, August 16, 2005; 143(4): 251 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Azziz, C. Marin, L. Hoq, E. Badamgarav, and P. Song Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4650 - 4658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Herman, T. J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R. F. Hamman, R. T. Ackermann, M. M. Engelgau, R. E. Ratner, et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance Ann Intern Med, March 1, 2005; 142(5): 323 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wolf, M. R. Conaway, J. Q. Crowther, K. Y. Hazen, J. L.Nadler, B. Oneida, and V. E. Bovbjerg Translating Lifestyle Intervention to Practice in Obese Patients With Type 2 Diabetes: Improving Control with Activity and Nutrition (ICAN) study Diabetes Care, July 1, 2004; 27(7): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Centers for Disease Control and Prevention Primary Primary Prevention of Type 2 Diabetes Mellitus by Lifestyle Intervention: Implications for Health Policy Ann Intern Med, June 1, 2004; 140(11): 951 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang, M. M. Engelgau, S. L. Norris, E. W. Gregg, and K. M. Venkat Narayan Application of Economic Analysis to Diabetes and Diabetes Care Ann Intern Med, June 1, 2004; 140(11): 972 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan and W. H. Herman Screening for Diabetes: Can We Afford Not To Screen? Ann Intern Med, May 4, 2004; 140(9): 756 - 758. [Full Text] [PDF]
|
|
|
|
|
|
J. Lindstrom, A. Louheranta, M. Mannelin, M. Rastas, V. Salminen, J. Eriksson, M. Uusitupa, and J. Tuomilehto The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity Diabetes Care, December 1, 2003; 26(12): 3230 - 3236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Prevention of Obesity and Diabetes Diabetes Care, November 1, 2003; 26(11): 3172 - 3178. [Full Text] [PDF]
|
|
|
|
|
|
Diabetes Prevention Program Research Group Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes Diabetes Care, September 1, 2003; 26(9): 2518 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Teutsch The Cost-Effectiveness of Preventing Diabetes Diabetes Care, September 1, 2003; 26(9): 2693 - 2694. [Full Text] [PDF]
|
|
|
|
|
|
S. Teutsch The Cost of Preventing Diabetes: What do we know and what do we need to know? Diabetes Care, January 1, 2003; 26(1): 238 - 239. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |